Skip to main content

Table 2 Important agents currently enrolling patients in clinical trials for systemic lupus erythematosus as of November 2010

From: Advances in drug therapy for systemic lupus erythematosus

Target Trial Comment
T cells NCT007744752 Abatacept
  NCT00774943 Amgen 557 ICOS inhibitor
B cells NCT00660881 Epratuzumab (anti-CD22)
  NCT00624338 Atacicept blocks BlyS and APRIL
  NCT01162681 A-623 blocks BlyS and APRIL
  NCT01205348 LY2127399 blocks BlyS
Toleragen NCT01085097 Laquinomod
  NCT01135459 Lupuzor tolerizes splicosome
Innate immunity NCT00962832 Rontalizumab inhibits IFN-α
  NCT01164917 Amgen 811 targets IFN-γ
  NCT00960362 NNCO152 targets IFN-α
  NCT01031836 MEDI-545 targets IFN-α
Cell surface receptor NCT0077194 Rapamycin targets mTOR
  1. aICOS, ; BlyS, B lymphocyte stimulation; APRIL, ; mTOR (mammalian target of rapamycin).